OBR Daily Commentary

forumImage

Endocyte Adds Phase 3-Ready Prostate Cancer Drug with ABX Deal

(Xconomy Indiana) Oct 2, 2017 - Four months after two Endocyte drug candidates stumbled in early-stage studies, sparking a corporate shakeup, the company has signed a deal landing an experimental prostate cancer treatment that it says is ready for Phase 3 clinical trials.

Read Article arrow

Dean Gesme, MD (Posted: October 02, 2017)

quotesEarly results affirm that this new agent might offer additive benefits in the evolution of serial therapies for castrate resistant prostate cancer.quotes

Add Comment 1 Comment
forumImage

Phase III Trial Confirms Pelvic Radiation As Standard Of Care For High-Risk, Early-Stage Endometrial Cancer

(ASTRO 59th Annual Meeting) Sept 25, 2017 - In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal cuff brachytherapy plus chemotherapy when compared with pelvic radiation therapy.

Read Article arrow

Dean Gesme, MD (Posted: September 26, 2017)

quotesLower radiation doses in HPV+ Head & Neck cancer would dramatically reduce toxicity and expense of treating this rapidly increasing virally related malignancy. Potentially practice changing with additional confirmatory data.quotes

Add Comment 1 Comment
forumImage

Bayer Secures One-Two Treatment For Liver Cancer After EU Approval

(Pharmafile [UK]) Aug 7, 2017 - Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver cancer, as second-line treatment. This means that Stivarga will be available to use after Bayer’s other therapy, Nexavar, used in first-line treatment.

Read Article arrow

Dean Gesme, MD (Posted: August 07, 2017)

quotesAfter a decade with only sorafenib for advanced HCC, it is refreshing to have several promising new targeted drugs and immunotherapies vying for first and second line status in this disease.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...